Skip to main content

Table 4 Bleeding characteristics and clinical outcome of patients in the UI-EWD monotherapy group

From: Hemostatic efficacy and safety of the hemostatic powder UI-EWD in patients with lower gastrointestinal bleeding

Variables

UI-EWD monotherapy (n = 17)

Location of bleeding, n (%)

Hepatic flexure

2 (11.8)

Transverse colon

3 (17.6)

Sigmoid colon

4 (23.5)

Rectum

8 (47.6)

Cause of bleeding, n (%)

Ulcer bleeding

2 (11.8)

Post procedure bleeding

10 (58.8)

Tumor bleeding

5 (29.4)

Size of bleeding site, n (%)

 < 1 cm

1 (5.9)

1–4 cm

10 (58.8)

 > 4 cm

6 (35.3)

Forrest classification, n (%)

Ia

0 (0.0)

Ib

17 (100.0)

Cumulative re-bleeding, n (%)

At 7 days

0 (0.0)

At 14 days

0 (0.0)

At 28 days

0 (0.0)

Time to re-bleeding (days)§

Adverse event, n (%)

Colonic obstruction

0 (0.0)

Perforation

0 (0.0)

Infection

0 (0.0)

Embolization

0 (0.0)

  1. §Median (range)
  2. +Fisher’s exact test
  3. *P-values were calculated using the t-test or Fisher calculated using the of the conventional therapy group and the UI-EWD therapy group